Nasdaq
$7.77▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $448.2MShares out 57.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
47- 10.6Pre-market26.10.06 20:006-KKey event#●●●#●●●
KAMADA LTDBullish
Kamada has expanded its biosimilar portfolio with the commercial launch of two additional products, Ustekinumab-Kamada and Enoxaparin-Kamada, in the Israeli market. The company projects that its biosimilar portfolio will generate approximately $10 million in annual revenue by 2028 and between $20 million and $25 million by 2030.…more
$7.77+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:006-KKey event
KAMADA LTD
Kamada has submitted its response to an SEC comment letter regarding accounting policies in its 2025 Form 20-F filing. The company plans to enhance its future disclosures concerning the capitalization criteria and accounting treatment for inventory produced prior to regulatory approval.…more
$7.77+0.00%vs prev closeView filingShare - 9.29Pre-market26.09.29 22:274Ownership
KAMADA LTD
Kamada Ltd insider Asher-Topilsky Lilach reported a change in beneficial ownership of securities as of August 27, 2026. This filing serves as the official disclosure of the insider's equity transaction via Form 4.…more
$7.77+0.00%vs prev closeView filingShare
46 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:00#●●●#●●●
Kamada Announces Participation in November Healthcare Investor Conferences…more
Kamada CEO Amir London will participate in the Stifel and Jefferies healthcare conferences in November to engage with investors. This announcement is a routine corporate update and does not contain material financial news affecting the stock price.…more
$7.77+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 20:00
●●●●●●●● ●●●●● ●●●●●●
Kamada has expanded its biosimilar portfolio with the commercial launch of two new products in Israel. The company projects that this strategic portfolio will generate between $20 million and $25 million in annual revenue by 2030.…more
$7.77+0.00%vs prev close - 9.17Pre-market26.09.17 20:00
●●●●●●●● ●●●●● ●●●●●●
Following a CDC report on the significant increase in U.S. rabies exposures, Kamada confirmed it has sufficient inventory and manufacturing capacity to meet the rising demand for its KedRAB treatment. This assurance highlights the company's ability to maintain supply stability in a growing market.…more
$7.77+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report